The Bristol Myers Squibb Foundation and National Medical Fellowships Launch $100 Million Program to Help Increase Diversity and Inclusion in Clinical Trials

Initiative will train 250 new clinical investigators and work within communities to build capacity to serve underrepresented patient populations

The Bristol Myers Squibb Foundation and National Medical Fellowships today announced that they have entered into a partnership aimed at improving diversity in clinical trials. Leveraging $100 million of the previously announced commitment from Bristol Myers Squibb and the Bristol Myers Squibb Foundation to diversity and inclusion, the partnership will develop a program to extend the reach of clinical trials into underserved patient populations in urban and rural U.S. communities. This program will train and develop 250 new clinical investigators who are racially and ethnically diverse or who have a demonstrated commitment to increasing diversity in clinical trials, and it will expose 250 promising, underrepresented minority medical students across the country to clinical research career pathways. Additionally, the program will assist program investigators in building capacity and standing up new clinical trials sites in communities with diverse and heavily burdened patient populations.

The need for diversity in clinical trials

"Clinical research is necessary to generate evidence demonstrating the efficacy and safety of new treatments," said Robert Winn, M.D., Director, Massey Cancer Center, Virginia Commonwealth University, who is serving as chair of the national advisory committee of the Bristol Myers Squibb Foundation Diversity in Clinical Trials Career Development Program. "While the patient response to medical therapies may differ across racial and ethnic subgroups, clinical trials often fail to represent the demographic diversity of the populations that these products aim to serve. I am proud to serve as an advisor to this program, which will support improvements toward diverse representation in clinical research and promote health equity."

In fact, aggregated data on the racial and ethnic participation in clinical trials published by the FDA show that in general 80% of patients taking part in clinical trials are white. Black Americans represent 13% 1 of the US population but only reflect about 7% 2 of participants in clinical trials.

John Damonti, president of the Bristol Myers Squibb Foundation added, "Science demonstrates that we must diversify clinical trials in order to improve health outcomes and advance health equity. We are pleased to partner with National Medical Fellowships so that this effort will benefit from their decades of experience and unmatched expertise. Together, we will tap the often overlooked but powerful resource of racially and ethnically diverse physicians or other physicians who have a demonstrated commitment to increasing diversity in clinical trials, working in academic medical centers, community-based practices and Federally Qualified Health Centers. These physicians are established in their communities, and no one is in a better position to build trusting relationships with patients than they are."

"Diversity has a role to play in the entire lifecycle of therapeutic development, from the trial design and community engagement, to therapeutic efficacy and adoption," said Sandra Nichols, M.D., Chairperson, National Medical Fellowships Board of Directors. "National Medical Fellowships has a vision to promote equity of access to quality healthcare for all groups in American society. Advancing diversity in clinical trials is a critically important component of this effort, and our partnership with the Bristol Myers Squibb Foundation is consistent with our mission."

About the program

The goal of the Bristol Myers Squibb Foundation Diversity in Clinical Trials Career Development Program is to increase diversity of patients enrolled in clinical trials, and ultimately enhance the development of therapeutics for all populations. The program will collaborate with communities to facilitate an approach to clinical and translational research that is community-informed, designed and conducted. It will provide the sponsorship, support and tools that emerging investigators need to conduct clinical trials that will yield the development of new treatments that are effective in all populations.

How to apply

Applications will open in January 2021. Eligible candidates will hold the degree of MD, MD/PhD, DO or DO/PhD and have an interest in clinical research in the areas of cancer (hematology and oncology), cardiovascular disease and immunologic disorders. In addition, they will reflect the NIH definition of Early Stage Investigator and the NIH definition of underrepresented populations in the U.S. Biomedical, Clinical Behavioral and Social Sciences Research Enterprise, or have a demonstrated commitment to increasing diversity in clinical trials. To learn more about eligibility and program details, please email DCTCDPinfo@nmfonline.org .

About the Bristol Myers Squibb Foundation

The Bristol Myers Squibb Foundation is committed to improving the health outcomes of populations disproportionately affected by serious diseases by strengthening healthcare worker capacity, integrating medical care and community-based supportive services, and addressing unmet medical need.

National Medical Fellowships

Seeking to empower and support aspiring physicians and health professionals underrepresented in medicine to contribute to the health of our nation, National Medical Fellowships' mission is to provide scholarships and support for underrepresented minority students in medicine and the health professions.

Founded in 1946, NMF was one of America's first diversity organizations. Today, as we come together to celebrate our diversity with joy and new purpose, NMF remains the only national organization solely dedicated to providing scholarships to medical and health professions students in all groups underrepresented in healthcare.

NMF is supported by a national network of Alumni who serve tens of millions of patients annually. Their experience inspires us and gives voice to our mission.

philathropy-news

1 https://www.census.gov/newsroom/releases/archives/2010_census/cb11-cn125.html
2 https://www.fda.gov/media/143592/download

BRISTOL MYERS SQUIBB FOUNDATION
MEDIA: media@bms.com

News Provided by Business Wire via QuoteMedia

The Conversation (0)
  BPH Global Ltd

Notice of Extraordinary General Meeting/Proxy Form

Notice is hereby given that an Extraordinary General Meeting of Shareholders of BPH Global Limited ACN 009 104 330 will be held at 3:00pm AEST on 24 May 2024 at Suite 5, Level 12, 530 Collins Street, Melbourne VIC 3000 (Meeting).

Keep reading...Show less
Genes and chromosomes with "2024" overlay.

Biotech Market Update: Q1 2024 in Review

The first quarter of 2024 witnessed a surge in initial public offerings (IPOs) and mergers and acquisitions (M&A) within the biotech industry, signaling continued interest from investors.

AstraZeneca’s acquisition of start-up Amolyt on March 14, and its longtime biotech partner Fusion Pharmaceuticals for US$2.4 billion on March 19 marked the third acquisition of a radiopharmaceutical developer in recent months. As of writing, there have been 14 M&A deals struck in 2024, according to data from Biopharma Dive.

Investment bank Jefferies released data in early March revealing that the sector was on track to earn its highest quarterly total in three years, reflecting the cautiously optimistic outlook at this year's JPM24 conference.

Keep reading...Show less

AMGEN TO PRESENT TEZSPIRE® PHASE 2A COPD DATA AT ATS 2024

Planning Underway for Phase 3 Development of Tezepelumab in COPD

Amgen (NASDAQ:AMGN) today provided an update regarding the results of the Phase 2a COURSE trial for TEZSPIRE ® (tezepelumab-ekko) in chronic obstructive pulmonary disease (COPD), which were accepted for presentation in the Clinical Trials Symposium at The American Thoracic Society (ATS) 2024 International Conference on Monday, May 20 from 9:15-11:15 a.m. PDT .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Close up 3D rendering of DNA strands.

Biotech Stocks: 5 Biggest Companies in 2024

What are the top biotech companies? The following five stocks have market capitalizations worth billions of dollars and operate in countries all around the globe.

Plus, these big-name biotech players have pipelines stuffed with potentially disruptive products — and enough revenue to recover should some of those products fail.

This means that investors can experience the excitement of biotech investing while minimizing risk. Although returns are never guaranteed, company size can insulate investors from volatility.

Keep reading...Show less
SIRONA BIOCHEM Corporate Update April 2024

SIRONA BIOCHEM Corporate Update April 2024

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (OTC: SRBCF) (" Sirona " or the " Company ") provides the following update:

Dear shareholders,

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Sirona Biochem Announces Close of Private Placement

Sirona Biochem Announces Close of Private Placement

Vancouver, British Columbia – April 4, 2024 Sirona Biochem Corp . (TSX-V: SBM) (Frankfurt: ZSB) (" Sirona ") has closed its private placement (Private Placement") for gross proceeds of $132,500 CAD. The Private Placement consists of 1,325,000 units, (the "Units") at a price of $0.10 per Unit. Each Unit consists of one common share and one transferable share purchase warrant, each whole warrant exercisable into one additional common share of the Company for a period of 2 years from the date of issue at a price of $0.15 per Share in year one and $0.25 per Share in year two. All securities issued under the Private Placement are subject to statutory hold periods expiring on August 4, 2024.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×